Thresholds for identifying stage B HF include BNP ≥ 50 pg/mL, NT-proBNP ≥ 125 pg/mL, and hs-cTn ≥ 99th percentile of the upper reference limit of the assay (84).Several studies have evaluated the combination of biomarkers with risk scoring models or the use of multiple biomarkers to predict HF risk in patients with T2DM (67, 69). This evidence concerns the gene NPPB and hydrops fetalis.